Longboard Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Longboard Pharmaceuticals's earnings have been declining at an average annual rate of -33.5%, while the Pharmaceuticals industry saw earnings growing at 1.2% annually.
Key information
-33.5%
Earnings growth rate
13.1%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | n/a |
| Return on equity | -27.7% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Longboard Pharma's Lucrative Exit To Lundbeck Another Coup For Management
Oct 15My Strategy For Longboard Pharmaceuticals After Its Big Run
Aug 28We Think Longboard Pharmaceuticals (NASDAQ:LBPH) Can Afford To Drive Business Growth
Jul 12
Longboard Pharmaceuticals: After Stellar Gains, A Period Of Relative Calm Seems Likely
Mar 16Will Longboard Pharmaceuticals (NASDAQ:LBPH) Spend Its Cash Wisely?
Oct 03We're Keeping An Eye On Longboard Pharmaceuticals' (NASDAQ:LBPH) Cash Burn Rate
Dec 25Companies Like Longboard Pharmaceuticals (NASDAQ:LBPH) Are In A Position To Invest In Growth
Sep 10We're Hopeful That Longboard Pharmaceuticals (NASDAQ:LBPH) Will Use Its Cash Wisely
May 28Longboard Pharmaceuticals (NASDAQ:LBPH) Is In A Good Position To Deliver On Growth Plans
Feb 11Here's Why We're Not At All Concerned With Longboard Pharmaceuticals' (NASDAQ:LBPH) Cash Burn Situation
Oct 27Longboard Pharmaceuticals (NASDAQ:LBPH) Is In A Strong Position To Grow Its Business
Jun 12Longboard Pharmaceuticals EPS beats by $0.29
May 10Revenue & Expenses Breakdown
How Longboard Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -76 | 20 | 67 |
| 30 Jun 24 | 0 | -65 | 17 | 56 |
| 31 Mar 24 | 0 | -58 | 15 | 48 |
| 31 Dec 23 | 0 | -54 | 13 | 44 |
| 30 Sep 23 | 0 | -51 | 12 | 41 |
| 30 Jun 23 | 0 | -49 | 12 | 40 |
| 31 Mar 23 | 0 | -46 | 11 | 36 |
| 31 Dec 22 | 0 | -44 | 10 | 35 |
| 30 Sep 22 | 0 | -41 | 10 | 32 |
| 30 Jun 22 | 0 | -36 | 10 | 27 |
| 31 Mar 22 | 0 | -32 | 9 | 22 |
| 31 Dec 21 | 0 | -28 | 8 | 20 |
| 30 Sep 21 | 0 | -29 | 6 | 16 |
| 30 Jun 21 | 0 | -25 | 5 | 13 |
| 31 Mar 21 | 0 | -20 | 4 | 9 |
Quality Earnings: LBPH is currently unprofitable.
Growing Profit Margin: LBPH is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: LBPH is unprofitable, and losses have increased over the past 5 years at a rate of 33.5% per year.
Accelerating Growth: Unable to compare LBPH's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: LBPH is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (54.6%).
Return on Equity
High ROE: LBPH has a negative Return on Equity (-27.74%), as it is currently unprofitable.